Value-based care strategies will continue to progress no matter who occupies the White House, according to Gail Wilensky, PhD, of Project HOPE. HHS Secretary Tom Price has indicated his support for limited demonstrations, but Wilensky predicts he will continue to push against large-scale mandatory demonstrations.
Value-based care strategies will continue to progress no matter who occupies the White House, according to Gail Wilensky, PhD, of Project HOPE. HHS Secretary Tom Price has indicated his support for limited demonstrations, but Wilensky predicts he will continue to push against large-scale mandatory demonstrations.
Transcript (slightly modified)
Do you think the country’s trajectory over the past few years toward value-based care will continue under the new administration?
I think we are on value-based care as where we need to be going forward, no matter who is running the administrations. We’re not quite as advanced as we like to talk about it. Most of the people who are doing value-based care strategies still reimburse their physicians using fee-for-service, which is not particularly compatible with value-based care, so we’re talking a little better game than we’re actually doing, but I don’t see us moving backward from where we are. It’s a question of how fast, how aggressively we’ll move forward to being really serious about purchasing value-based care.
What impact do you think HHS Secretary Tom Price, MD, will have on new payment model pilots?
The question about whether Dr Price, Secretary Price now, will pull back from pilots has been raised a lot. I think what he is likely to move away from are the mandatory demonstrations, which had been raised at the end of the Obama administration, and which have an appeal in that they don’t have to contend with self-selection as an issue. But I’m not sure they’re as critical as they’re sometimes made out to be.
His point, and I have some sympathy with this, is that by having large-scale, mandatory demonstrations, you’re basically taking away the right of Congress to make changes in reimbursement, and that, more than potentially limited mandatory demonstrations or voluntary demonstrations, is what he was pushing against, as well as the other Republican members of the Congress.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More